AOD-9604 is a synthetic peptide originally developed to investigate the fat-metabolism effects of human growth hormone (HGH). Unlike full-length HGH, it was designed to target certain metabolic processes without producing the same growth-related hormonal activity.
Researchers have examined several potential AOD-9604 benefits, including increased fat breakdown, reduced fat storage, and changes in energy metabolism. Early animal studies produced encouraging findings, but subsequent human trials delivered mixed results.
One of the largest clinical studies failed to demonstrate a significant weight-loss benefit compared with placebo.
So, what does AOD-9604 actually do, and which potential benefits have scientific support?
This article examines the biological activity of AOD-9604, its potential benefits, human clinical findings, and important safety considerations.
What Is AOD-9604 and How Does It Work?
AOD-9604, also known as Anti-Obesity Drug 9604, is a modified fragment derived from the C-terminal region of human growth hormone.
The peptide is based on amino acids 177–191 of HGH, with an additional tyrosine residue.
Human growth hormone participates in several biological functions, including tissue growth, protein metabolism, fat utilization, and glucose regulation.
Researchers developed AOD-9604 to investigate whether HGH’s effects on lipid metabolism could be separated from its influence on growth and insulin-like growth factor 1 (IGF-1).
Laboratory investigations suggest that AOD-9604 can influence fat metabolism through mechanisms associated with lipolysis and fat oxidation.
However, its precise mechanism of action has not been fully established.
1. AOD-9604 May Influence Lipolysis
One of the most frequently discussed potential benefits of AOD-9604 is its effect on lipolysis.
Lipolysis is the biological process through which stored triglycerides are broken down into fatty acids and glycerol.
These fatty acids can subsequently be used as an energy source under appropriate metabolic conditions.
What Does the Research Show?
A 2001 study published in Endocrinology investigated the effects of AOD-9604 on lipid metabolism in obese mice.
Researchers observed increased lipolytic sensitivity and reductions in body fat after repeated administration.
The findings also suggested a possible relationship between AOD-9604 and beta-3 adrenergic receptors, which are involved in regulating fat-cell activity.
However, the researchers found that some metabolic effects could occur even in mice lacking these receptors, suggesting that the mechanism is more complex than a single receptor pathway.
What this means: AOD-9604 demonstrated lipolytic activity in experimental animal models. However, these findings do not prove that the peptide increases fat breakdown to a clinically meaningful degree in humans.
Research reference: Heffernan et al., 2001 – PubMed
2. Potential Effects on Fat Storage and Lipogenesis
Another area of AOD-9604 research involves lipogenesis.
While lipolysis describes the breakdown of stored fat, lipogenesis involves the synthesis of fatty acids and their incorporation into stored triglycerides.
Both processes contribute to the body’s overall fat balance.
Early experimental studies suggested that the HGH fragment associated with AOD-9604 could reduce lipogenic activity under certain conditions.
These findings led researchers to investigate whether AOD-9604 might influence fat storage independently of the growth-promoting effects of complete HGH.
Can AOD-9604 Prevent Fat Accumulation?
There is currently no reliable human clinical evidence demonstrating that AOD-9604 prevents fat accumulation.
Although experimental investigations reported changes in fat metabolism, the results were not consistently reproduced as meaningful weight-loss outcomes in larger human trials.
Therefore, claims that AOD-9604 blocks fat storage or prevents fat gain in humans go beyond the available clinical evidence.
3. AOD-9604 and Body Weight: What Human Trials Found
Weight management was the primary reason AOD-9604 entered clinical development.
Researchers initially hoped that the peptide could reproduce some of HGH’s effects on lipid metabolism without producing its broader hormonal effects.
Several clinical trials were conducted to evaluate this possibility.
Findings From the 12-Week Trial
An earlier Phase IIb study involved approximately 300 adults with obesity.
Participants received different oral doses of AOD-9604 or placebo over 12 weeks.
The study reported a greater average reduction in body weight in one AOD-9604 treatment group compared with placebo.
However, the results were inconsistent across different dosage groups.
Higher doses did not consistently produce greater effects, making it difficult to identify a clear relationship between AOD-9604 exposure and weight reduction.
Findings From the Larger 24-Week Trial
A subsequent study involving 502 adults evaluated daily oral administration over 24 weeks.
This trial was particularly important because it included a larger study population and a longer treatment period.
The trial failed to demonstrate a statistically significant weight-loss benefit compared with placebo.
Following these results, development of AOD-9604 as an obesity treatment was discontinued in 2007.
What Can We Conclude?
The early results suggested a possible effect on body weight, but the larger trial did not confirm that benefit.
AOD-9604 has not been shown to produce reliable, clinically meaningful weight loss in humans.
It should not be described as a proven fat-loss treatment or an established alternative to FDA-approved weight-management medications.
Research reference: Stier et al., 2013 – Safety and Tolerability of AOD9604 in Humans
4. Potential Influence on Fat Oxidation and Energy Metabolism
Fat oxidation is the process through which fatty acids are broken down to produce usable energy.
Because AOD-9604 was developed from a metabolically active region of HGH, researchers investigated whether it could influence fat oxidation and energy expenditure.
Animal studies reported changes in fat oxidation after AOD-9604 administration.
In some experimental models, these findings were accompanied by changes in body fat and metabolic responses.
One particularly interesting finding came from research involving genetically modified mice lacking beta-3 adrenergic receptors.
Although these animals did not demonstrate the same long-term changes in body weight, some acute effects on energy expenditure and fat oxidation were still observed.
This suggests that AOD-9604 may interact with multiple biological pathways.
Does AOD-9604 Increase Metabolism in Humans?
There is insufficient clinical evidence to establish that AOD-9604 meaningfully increases metabolic rate or daily energy expenditure in humans.
Animal findings provide a scientific reason to investigate the peptide, but they cannot establish a therapeutic benefit.
5. AOD-9604 May Have Different Effects on IGF-1 Than Full-Length HGH
AOD-9604 was designed to preserve selected metabolic actions of HGH while avoiding some of its growth-related effects.
One important area of investigation involved insulin-like growth factor 1, commonly known as IGF-1.
IGF-1 is a hormone that supports growth, cellular development, and several anabolic processes.
Full-length human growth hormone stimulates IGF-1 production, particularly in the liver.
AOD-9604 does not appear to produce the same effect.
What Did Clinical Studies Find?
A 2013 analysis reviewed six randomized, double-blind, placebo-controlled trials involving a total of 893 participants.
Researchers specifically examined whether AOD-9604 influenced serum IGF-1 concentrations.
They found no significant increase in IGF-1 levels associated with AOD-9604 administration.
This supports the hypothesis that AOD-9604 does not reproduce the full biological activity of HGH.
Why Is This Finding Important?
The results helped researchers distinguish the peptide’s biological activity from the broader hormonal effects of HGH.
However, the absence of an IGF-1 increase should not be interpreted as proof that AOD-9604 is safer than HGH in every clinical situation.
Its overall safety profile remains incompletely characterized, particularly for injectable formulations and long-term administration.
6. AOD-9604 and Glucose Metabolism
Human growth hormone can influence glucose metabolism and insulin sensitivity.
Elevated HGH exposure may impair insulin sensitivity in certain circumstances, which can affect blood glucose regulation.
For this reason, researchers examined whether AOD-9604 produced similar metabolic effects.
Findings From Human Research
Clinical investigators conducted oral glucose tolerance tests to assess how participants responded to glucose exposure.
The 2013 safety review reported no significant adverse effects on glucose tolerance in the studied populations.
Researchers also found no clinically meaningful differences between treatment groups and placebo in several evaluated glucose-related measurements.
These findings suggest that AOD-9604 did not reproduce certain glucose-related effects associated with full-length HGH during the studied treatment periods.
Does AOD-9604 Improve Insulin Sensitivity?
There is insufficient evidence to conclude that AOD-9604 improves insulin sensitivity or treats insulin resistance.
The available studies primarily examined whether the peptide negatively affected glucose metabolism.
Not worsening glucose tolerance is different from improving glucose control.
AOD-9604 is not an established treatment for diabetes, insulin resistance, or other glucose-related disorders.
7. AOD-9604 and Cartilage or Joint Health
Some discussions of AOD-9604 mention possible benefits for cartilage, connective tissue, and joint function.
These claims are less established than the peptide’s research on lipid metabolism.
Certain experimental investigations have explored whether growth hormone fragments may influence cartilage-related biological processes.
However, research findings involving isolated cells or animal models do not demonstrate that AOD-9604 improves joint health in humans.
There is currently insufficient high-quality clinical evidence showing that AOD-9604:
- Repairs damaged cartilage.
- Improves osteoarthritis symptoms.
- Accelerates joint recovery.
- Reduces joint pain.
- Restores connective tissue function.
These remain unproven therapeutic claims.
Patients experiencing joint pain or mobility problems should seek a medical evaluation rather than rely on investigational peptides with uncertain effectiveness.
8. What Are the Potential Benefits of AOD-9604 for Muscle Growth?
AOD-9604 is sometimes discussed alongside HGH and other peptides used in research involving body composition.
However, it is important to distinguish AOD-9604 from full-length human growth hormone.
HGH participates in several anabolic pathways, including those involving IGF-1.
AOD-9604 was developed to investigate selected metabolic actions without substantially stimulating those growth-related pathways.
Clinical studies have not established that AOD-9604 increases muscle mass, strength, or exercise performance.
There is also no convincing evidence that it improves muscle recovery after exercise.
Therefore, AOD-9604 should not be presented as a proven muscle-building or performance-enhancing therapy.
9. What Do Clinical Studies Say About AOD-9604 Safety?
Safety is an essential part of evaluating any investigational peptide.
A 2013 review of six human clinical trials reported generally favorable tolerability for the formulations and administration routes studied.
The review examined several important safety measurements, including:
- Serum IGF-1 concentrations.
- Glucose tolerance.
- Clinical laboratory measurements.
- Vital signs.
- Electrocardiogram findings.
- Treatment-related adverse events.
- Antibody formation.
Researchers reported no treatment-related serious adverse events or withdrawals across the reviewed trials.
Anti-AOD-9604 antibodies were not detected in the subset of participants selected for antibody testing.
However, these findings have important limitations.
Safety of Oral and Injectable AOD-9604 May Differ
Most longer-duration human studies used oral formulations.
There is much less published evidence examining repeated subcutaneous injections.
The FDA has identified potential safety concerns associated with compounded AOD-9604, including immunogenicity and risks related to impurities or peptide aggregation.
Consequently, favorable findings from historical oral trials cannot establish the safety of injectable AOD-9604 products.
Long-term safety also remains uncertain.
10. Is AOD-9604 FDA-Approved?
No. AOD-9604 is not approved by the U.S. Food and Drug Administration for any therapeutic indication.
It has no FDA-approved prescribing information, recommended dosage, or established clinical treatment protocol.
In December 2024, the FDA’s Pharmacy Compounding Advisory Committee reviewed AOD-9604-related bulk drug substances as part of its evaluation of ingredients nominated for pharmacy compounding.
FDA’s evaluation discussed concerns involving:
- Limited evidence of clinical effectiveness.
- Incomplete safety information for proposed administration routes.
- Potential immunogenicity.
- Peptide-related impurities and aggregation.
- Inadequate characterization of certain formulations.
Patients should understand that investigational status and historical clinical testing do not establish that a peptide is appropriate for routine medical use.
AOD-9604 Benefits: Frequently Asked Questions
What are the main potential benefits of AOD-9604?
AOD-9604 has shown potential effects on lipolysis, fat oxidation, and lipid metabolism in laboratory and animal studies. However, these findings have not established clinically meaningful benefits in humans.
Does AOD-9604 help with belly fat?
There is no convincing clinical evidence demonstrating that AOD-9604 selectively reduces abdominal fat in humans. Claims of targeted belly-fat reduction are not supported by reliable clinical trials.
Does AOD-9604 increase metabolism?
Some animal studies reported changes in fat oxidation and energy expenditure. However, human studies have not established that AOD-9604 meaningfully increases metabolic rate.
Is AOD-9604 better than HGH?
AOD-9604 and HGH have different biological activities. AOD-9604 did not significantly increase IGF-1 in the reviewed human studies, but that does not make it a better or safer treatment. The two substances are not clinically interchangeable.
Can AOD-9604 increase muscle mass?
There is insufficient human clinical evidence showing that AOD-9604 increases lean muscle mass, strength, or physical performance.
Is AOD-9604 safe for long-term use?
Long-term safety has not been established. Historical trials reported generally favorable tolerability, but uncertainties remain regarding prolonged exposure, injectable formulations, immunogenicity, and product quality.
Can AOD-9604 improve insulin sensitivity?
Human trials did not demonstrate significant adverse effects on glucose tolerance, but this does not establish that AOD-9604 improves insulin sensitivity or treats metabolic disorders.
How long does it take to see AOD-9604 benefits?
There is no established timeline for clinical benefits. Larger controlled studies failed to confirm consistent weight-loss effectiveness, and no approved therapeutic regimen exists.
Final Thoughts: Are AOD-9604 Benefits Supported by Science?
AOD-9604 remains an interesting investigational peptide because of its biological relationship to human growth hormone and its effects on lipid metabolism in experimental models.
Preclinical research has identified possible activity involving fat breakdown, fat oxidation, and metabolic signaling.
Human studies have also provided information about its effects on IGF-1 and glucose regulation.
However, the distinction between biological activity and demonstrated clinical benefits is essential.
Although initial human studies suggested possible weight-management effects, the larger 24-week trial failed to confirm significant effectiveness.
There is currently insufficient evidence to recommend AOD-9604 for fat reduction, muscle growth, metabolic improvement, or other therapeutic purposes.
At Optimal HRT, we emphasize evidence-based approaches to metabolic health, hormone evaluation, and personalized medical care. Understanding what research supports—and where important questions remain—helps patients make more informed healthcare decisions.
Scientific References
1. Heffernan M, et al. (2001). The Effects of Human GH and Its Lipolytic Fragment (AOD9604) on Lipid Metabolism Following Chronic Treatment in Obese Mice and Beta(3)-AR Knock-Out Mice. Endocrinology, 142(12), 5182–5189.
2. Stier H, Vos E, Kenley D. (2013). Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Journal of Endocrinology and Metabolism, 3(1–2), 7–15.
https://doi.org/10.4021/jem157w
3. Moré et al. (2014). Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health. Journal of Endocrinology and Metabolism.
https://www.jofem.org/index.php/jofem/article/view/213/278
4. U.S. Food and Drug Administration. (2024). Pharmacy Compounding Advisory Committee: AOD-9604-Related Bulk Drug Substances.
Medical Disclaimer: This article is intended for educational purposes only and does not constitute medical advice. AOD-9604 is not FDA-approved for medical treatment. Its safety and effectiveness for clinical use have not been established. Consult a qualified healthcare professional about evidence-based treatment options.
